Head-to-head · WeighScore
Breeze Meds vs Zealthy
The verdict
Breeze Meds takes it — 72.4/100 to 46.7/100.
Breeze Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Charges nothing until a provider approves you — but keeps its pricing inside the intake.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Breeze Meds | Zealthy |
|---|---|---|
| WeighScore | 72.4/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #55 | #496 |
| Semaglutide | From $199/mo | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | From $299/mo first month, $399/mo thereafter | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | All 50 states | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #55 · C
Strengths
- Nothing charged until a provider approves you, and the consult is free if you go ahead
- One inclusive price covering consult, medication, supplies, shipping and support
- LegitScript certified, all 50 states, cancel or change plan at any time
- NAD+ injections offered alongside the GLP-1 line
Where it loses points
- The public site names no molecule behind its "from $199" — tirzepatide pricing appears only inside the intake
- Every quoted figure is for the LOWEST dose; the funnel says higher doses may cost more
- An $80 consultation fee applies if you are approved and then decline
- Injection only, compounded only, with no published lab programme
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.